Nyxoah gains FDA approval for its Genio system, signaling a major growth milestone. Explore revenue growth, risks, and why ...

Q2 2025 Earnings Call Transcript August 18, 2025 Nyxoah S.A. misses on earnings expectations. Reported EPS is $-0.63 EPS, ...

Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in ...

Nyxoah SA (NASDAQ:NYXH) is set to release its Q2 2025 earnings on Aug 18, 2025. The consensus estimate for Q2 2025 revenue is ...

Nyxoah ( ($NYXH) ) has provided an update. On August 18, 2025, Nyxoah SA announced its financial and operating results for the second quarter and ...

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to ...

Q2 2025 Earnings Conference Call August 18, 2025 4:30 PM ETCompany ParticipantsJohn Landry - Chief Financial OfficerOlivier ...

Analysts estimate that Nyxoah will report an earnings per share (EPS) of $-0.63. Nyxoah bulls will hope to hear the company ...

Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S.

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

Genio is a different approach to hypoglossal nerve stimulation (HGNS) for the treatment of OSA. Genio’s unique design utilizes bilateral stimulation, and offers patients a leadless, full-body 1.5T and ...